JPMorgan Raises Kymera Therapeutics Price Target to $141 From $140
Valid market news retained in the public archive without immediate LiveCast distribution.
Related stories
HL Mando Reports Q3 Loss; Shares Fall 3%
HL Mando reported a third-quarter 2026 loss compared with net income a year earlier. Shares were down 3%.
M impact | EQUITY | Oct 30, 2026, 07:41 AM UTC
AstraZeneca Reports Third-Quarter Revenue and Profit Growth
AstraZeneca said third-quarter revenue and profit increased, with strong cancer-drug sales offsetting the effect of patent expirations.
M impact | EQUITY | Oct 30, 2026, 07:40 AM UTC
South Korean Stocks Fall 3.5%, Down 16% This Month
South Korean shares closed down 3.5% Friday, bringing the month’s decline to 16%, as doubts about the global AI investment boom weighed on chipmakers.
M impact | EQUITY | Oct 30, 2026, 07:39 AM UTC
Ahold Delhaize to Acquire Tesco’s Czech and Slovak Operations
Ahold Delhaize will acquire Tesco’s operations in the Czech Republic and Slovakia.
M impact | EQUITY | Oct 30, 2026, 07:36 AM UTC
Varun Beverages Quarterly Profit Rises on Volume Growth
Packaging costs weighed on margins.
M impact | EQUITY | Oct 30, 2026, 07:35 AM UTC
Tesco Reports GBP2.9B Combined Sales in Czech Republic and Slovakia
M impact | EQUITY | Oct 30, 2026, 07:35 AM UTC